Company intelligence / Profile preview
Epigenesis Pharmaceuticals
Cranbury, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Epigenesis Pharmaceuticals specialized in developing inhaled respiratory medications for diseases such as asthma and COPD. Its most advanced program was an inhaled steroid candidate (“EPI 12323”) for asthma that entered Phase 2 trials but did not progress further. Several other programs were discontinued or remain at early stages.
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Epigenesis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epigenesis Pharmaceuticals.